Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis
- PMID: 3359945
- DOI: 10.2165/00003495-198800351-00010
Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis
Abstract
Tiaprofenic acid is a potent non-steroidal anti-inflammatory drug which, in conventional tablet form, has been shown to be rapidly absorbed and eliminated from the plasma, while synovial fluid concentrations remain constant for at least 8 hours. Recently, a sustained action formulation of tiaprofenic acid has been developed to provide the patient with the convenience of a once daily dosage. The purpose of this study was to measure plasma and synovial fluid concentrations over a 24-hour period following repeated administration of the sustained action formulation, and thus determine the pharmacokinetic profile. Eight patients suffering from rheumatoid arthritis were included in this open study (of whom 3 were subsequently excluded from the analysis). All were hospital outpatients requiring aspiration of the knee joint. The patients received sustained action tiaprofenic acid in a dosage of 600 mg once daily for a period of 7 days. Plasma and synovial fluid samples were taken on the final treatment day at 0, 4, 8, 12, and 18 hours following administration of the last treatment dose. Areas under the concentration-time curves, maximum plasma and synovial fluid concentrations, times to maximum concentration, and apparent elimination half-lives are presented and the findings compared and discussed. The drug was found to be retained in both the plasma and synovial fluid over a 24-hour period. Synovial fluid concentrations exceeded plasma concentrations at 24 hours in 4 of the 5 patients who were analysed, while in the fifth patient the levels were very similar.
Similar articles
-
Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.Clin Pharmacokinet. 1996 Nov;31(5):331-47. doi: 10.2165/00003088-199631050-00002. Clin Pharmacokinet. 1996. PMID: 9118583 Review.
-
Reduction of prostaglandin E2 concentrations in synovial fluid of patients suffering from rheumatoid arthritis following tiaprofenic acid or indomethacin treatment.Drugs. 1988;35 Suppl 1:4-8. doi: 10.2165/00003495-198800351-00004. Drugs. 1988. PMID: 3162870 Clinical Trial.
-
[Trans-synovial kinetics of tiaprofenic acid].Z Rheumatol. 1988 May-Jun;47(3):173-6. Z Rheumatol. 1988. PMID: 3213265 German.
-
Pharmacokinetics of lumiracoxib in plasma and synovial fluid.Clin Pharmacokinet. 2004;43(7):467-78. doi: 10.2165/00003088-200443070-00003. Clin Pharmacokinet. 2004. PMID: 15139795 Clinical Trial.
-
Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.Clin Pharmacokinet. 1999 Mar;36(3):191-210. doi: 10.2165/00003088-199936030-00002. Clin Pharmacokinet. 1999. PMID: 10223168 Review.
Cited by
-
Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases.Drugs. 1995 Dec;50(6):1050-75. doi: 10.2165/00003495-199550060-00010. Drugs. 1995. PMID: 8612471 Review.
-
Dermacase. Acanthosis nigricans.Can Fam Physician. 1995 Jan;41:59, 61. Can Fam Physician. 1995. PMID: 7894281 Free PMC article. No abstract available.
-
Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.Clin Pharmacokinet. 1996 Nov;31(5):331-47. doi: 10.2165/00003088-199631050-00002. Clin Pharmacokinet. 1996. PMID: 9118583 Review.
-
Dermacase. Contact photodermatitis.Can Fam Physician. 1995 Apr;41:577, 586-7. Can Fam Physician. 1995. PMID: 7787488 Free PMC article. No abstract available.
-
Symposium on therapeutic aspects of tiaprofenic acid.Drugs. 1988;35 Suppl 1:1-3. doi: 10.2165/00003495-198800351-00003. Drugs. 1988. PMID: 3282866 Review. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical